Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* CD20-positive follicular non-Hodgkin's lymphoma (NHL)~* Documented partial or complete response a the end of induction treatment with rituximab~* Must have completed induction treatment, and received at least 1 dose of intravenous rituximab maintenance treatment~* Eastern Cooperative Oncology Group (ECOG) performance status of less than and equal to (\<=) 2~* Life expectancy of greater than and equal to (\>=) 6 months~Exclusion Criteria:~* Histological evidence of transformation of NHL, or types of NHL other than follicular lymphoma~* Presence or history of central nervous system disease~* History of malignancy other than follicular NHL~* Recent major surgery (within 4 weeks prior to screening), excluding lymph node biopsy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab IV 375 mg/m^2 (Stage 1: Cohort A) (Type: ACTIVE_COMPARATOR): None
- Rituximab IV 375 mg/m^2 (Stage 2: Cohort E) (Type: ACTIVE_COMPARATOR): None
- Rituximab SC 1400 mg (Stage 2: Cohort F) (Type: EXPERIMENTAL): None
- Rituximab SC 375 mg/m^2 (Stage 1: Cohort B) (Type: EXPERIMENTAL): None
- Rituximab SC 625 mg/m^2 (Stage 1: Cohort C) (Type: EXPERIMENTAL): None
- Rituximab SC 800 mg/m^2 (Stage 1: Cohort D) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).